Whitney S Goldner1, Julie A Stoner2, Elizabeth Lyden3, Jon Thompson4, Karen Taylor4, Luann Larson5, Judi Erickson6, Corrigan McBride4. 1. Section of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 68198-3020, USA. wgoldner@unmc.edu. 2. Department of Biostatistics and Epidemiology, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 3. Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA. 4. Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA. 5. Clinical Research Center, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. 6. Section of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 68198-3020, USA.
Abstract
BACKGROUND:Vitamin D deficiency is common following bariatric surgery and is due to a combination of baseline deficiency and postoperative malabsorption. There are few prospective studies evaluating the appropriate dose of vitamin D to prevent and treat vitamin D deficiency following bariatric surgery. METHODS: We evaluated three doses of vitamin D3 (800, 2,000, and 5,000 IU/day) in a prospective, randomized pilot trial of 45 patients undergoing Roux-en-Y gastric bypass. Serum 25 hydroxy Vitamin D (25OHD), intact PTH (iPTH), calcium, and urine calcium/creatinine ratios were measured at 6, 12, and 24 months postoperatively. Due to a high dropout rate at 24 months, we focus on the 12-month data. RESULTS: At 12 months, the 800-, 2,000-, and 5,000-IU groups had a mean +/- SD increase in 25OHD of 27.5 +/- 40.0, 60.2 +/- 37.4, and 66.1 +/- 42.2 nmol/L, respectively (p = 0.09) with a maximum increase in each group of 87.4, 114.8, and 129.8 nmol/L. Forty-four percent, 78%, and 70% achieved 25OHD levels >or=75 nmol/L (p = 0.38). Results for the 6- and 24-month time points were similar to the 12-month results. Mean weight loss at 24 months of the study was not different among groups (p = 0.52). Serum calcium did not change significantly, and there were no cases of hypercalcemia or sustained hypercalciuria. CONCLUSIONS: Higher doses of vitamin D supplementation trend towards higher levels of 25OHD. Vitamin D replacement as high as 5,000 IU /day is safe and necessary in many patients to treat vitamin D deficiency following Roux-en-Y gastric bypass yet is still suboptimal in others.
RCT Entities:
BACKGROUND: Vitamin D deficiency is common following bariatric surgery and is due to a combination of baseline deficiency and postoperative malabsorption. There are few prospective studies evaluating the appropriate dose of vitamin D to prevent and treat vitamin D deficiency following bariatric surgery. METHODS: We evaluated three doses of vitamin D3 (800, 2,000, and 5,000 IU/day) in a prospective, randomized pilot trial of 45 patients undergoing Roux-en-Y gastric bypass. Serum 25 hydroxy Vitamin D (25OHD), intact PTH (iPTH), calcium, and urine calcium/creatinine ratios were measured at 6, 12, and 24 months postoperatively. Due to a high dropout rate at 24 months, we focus on the 12-month data. RESULTS: At 12 months, the 800-, 2,000-, and 5,000-IU groups had a mean +/- SD increase in 25OHD of 27.5 +/- 40.0, 60.2 +/- 37.4, and 66.1 +/- 42.2 nmol/L, respectively (p = 0.09) with a maximum increase in each group of 87.4, 114.8, and 129.8 nmol/L. Forty-four percent, 78%, and 70% achieved 25OHD levels >or=75 nmol/L (p = 0.38). Results for the 6- and 24-month time points were similar to the 12-month results. Mean weight loss at 24 months of the study was not different among groups (p = 0.52). Serum calcium did not change significantly, and there were no cases of hypercalcemia or sustained hypercalciuria. CONCLUSIONS: Higher doses of vitamin D supplementation trend towards higher levels of 25OHD. Vitamin D replacement as high as 5,000 IU /day is safe and necessary in many patients to treat vitamin D deficiency following Roux-en-Y gastric bypass yet is still suboptimal in others.
Authors: Jason M Johnson; James W Maher; Eric J DeMaria; Robert W Downs; Luke G Wolfe; John M Kellum Journal: Ann Surg Date: 2006-05 Impact factor: 12.969
Authors: C Poitou Bernert; C Ciangura; M Coupaye; S Czernichow; J L Bouillot; A Basdevant Journal: Diabetes Metab Date: 2007-01-26 Impact factor: 6.041
Authors: Juan Ybarra; Joan Sánchez-Hernández; Ignasi Gich; Alberto De Leiva; Xavier Rius; Jose Rodríguez-Espinosa; Antonio Pérez Journal: Obes Surg Date: 2005-03 Impact factor: 4.129
Authors: Arthur M Carlin; D Sudhaker Rao; Ali M Meslemani; Jeffrey A Genaw; Nayana J Parikh; Shiri Levy; Arti Bhan; Gary B Talpos Journal: Surg Obes Relat Dis Date: 2006-02-28 Impact factor: 4.734
Authors: Radmila Levinson; Jon B Silverman; Jennifer G Catella; Iwona Rybak; Hina Jolin; Kellene Isom Journal: Obes Surg Date: 2013-07 Impact factor: 4.129
Authors: Lingtak-Neander Chan; Charlotte H Neilson; Elizabeth A Kirk; Tiana F Colovos; Diane R Javelli; Saurabh Khandelwal Journal: Obes Surg Date: 2015-12 Impact factor: 4.129
Authors: H A Bischoff-Ferrari; A Shao; B Dawson-Hughes; J Hathcock; E Giovannucci; W C Willett Journal: Osteoporos Int Date: 2009-12-03 Impact factor: 4.507
Authors: Hinali Zaveri; Amit Surve; Daniel Cottam; Austin Cottam; Walter Medlin; Christina Richards; LeGrand Belnap; Samuel Cottam; Benjamin Horsley Journal: Obes Surg Date: 2018-10 Impact factor: 4.129
Authors: Jeffrey I Mechanick; Adrienne Youdim; Daniel B Jones; W Timothy Garvey; Daniel L Hurley; M Molly McMahon; Leslie J Heinberg; Robert Kushner; Ted D Adams; Scott Shikora; John B Dixon; Stacy Brethauer Journal: Obesity (Silver Spring) Date: 2013-03 Impact factor: 5.002
Authors: Jeffrey I Mechanick; Adrienne Youdim; Daniel B Jones; W Timothy Garvey; Daniel L Hurley; M Molly McMahon; Leslie J Heinberg; Robert Kushner; Ted D Adams; Scott Shikora; John B Dixon; Stacy Brethauer Journal: Endocr Pract Date: 2013 Mar-Apr Impact factor: 3.443